Diagnosis and treatment of malnutrition and sarcopenia in patients with hepatocellular carcinoma (HeCCMaST)

Diagnosis and treatment of malnutrition and sarcopenia in patients with hepatocellular carcinoma (HeCCMaST) - HeCCMaST

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00032221

Enrollment

Registered

2025-08-18

Start date

2022-08-11

Completion date

Unknown

Last updated

2025-10-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

C22

Interventions

Group 1: Follow-up observation of patients with hepatocellular carcinoma (HCC) at intervals of approximately 3 months, including assessment of malnutrition and sarcopenia, BIA, muscle strength, and mu

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Diagnosis of HCC based on clinical and imaging methods (sonography, NMR, CT)

Exclusion criteria

Exclusion criteria: - Pregnancy or breastfeeding - Pacemaker or implanted defibrillator - Insufficient ability to answer questionnaires

Design outcomes

Primary

Measure	Time frame
- Prevalence of malnutrition and sarcopenia in the course of the tumor disease	—

Secondary

Measure	Time frame
Difference pre-post after ~3, 6 months and possibly further time points after study inclusion: - Staging of underlying liver disease and HCC (MELD score, Child Pugh stage, TNM classification, BCLC stage, ALBI score, mRECIST, ECOG performance status) - Mortality and hospital readmissions - Determination of overall survival (OS) and progression-free survival (PFS) - Delta prevalence of diagnosis of malnutrition (GLIM criteria) and sarcopenia (EWGSOP2 criteria) - Delta prevalence of reduced skeletal muscle mass (70 years), unintentional weight loss (> 10 % regardless of the period or > 5 % in the last 3-6 months), reduced fat-free mass index (FFMI) < 15 kg/m2 (??), < 17 kg/m2 (??)) of the patients at the different time points - Difference in anthropometric parameters (body weight (kg), BMI (kg/m2), upper arm and calf circumference (cm)) - Differences in body composition (BIA): Fat mass (FM(I)), fat-free mass (FFM(I)), skeletal muscle mass (SMM(I)), body water (TBW), extracellular water (ECW), phase angle - Muscle strength via hand grip strength (kg) as the highest value of 3 measurements - Muscle function based on walking speed (4m walking distance, m/s) - Physical activity (IPAQ questionnaire); METs per day, activity level - Clinical-chemical blood analysis	—

Measure

Time frame

Difference pre-post after ~3, 6 months and possibly further time points after study inclusion: - Staging of underlying liver disease and HCC (MELD score, Child Pugh stage, TNM classification, BCLC stage, ALBI score, mRECIST, ECOG performance status) - Mortality and hospital readmissions - Determination of overall survival (OS) and progression-free survival (PFS) - Delta prevalence of diagnosis of malnutrition (GLIM criteria) and sarcopenia (EWGSOP2 criteria) - Delta prevalence of reduced skeletal muscle mass (70 years), unintentional weight loss (> 10 % regardless of the period or > 5 % in the last 3-6 months), reduced fat-free mass index (FFMI) < 15 kg/m2 (??), < 17 kg/m2 (??)) of the patients at the different time points - Difference in anthropometric parameters (body weight (kg), BMI (kg/m2), upper arm and calf circumference (cm)) - Differences in body composition (BIA): Fat mass (FM(I)), fat-free mass (FFM(I)), skeletal muscle mass (SMM(I)), body water (TBW), extracellular water (ECW), phase angle - Muscle strength via hand grip strength (kg) as the highest value of 3 measurements - Muscle function based on walking speed (4m walking distance, m/s) - Physical activity (IPAQ questionnaire); METs per day, activity level - Clinical-chemical blood analysis

—

Countries

Germany

Contacts

Public ContactGeorg Lamprecht

Universitätsmedizin Rostock, Department für Innere Medizin, Klinik und Poliklinik für Gastroenterologie, Hepatologie und Ernährungsmedizin

georg.lamprecht@med.uni-rostock.de+49 381 494 7481

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026